IL1B and colitis: In animal models, wedelolactone alleviated DSS-induced colitis by blocking NF-κB and MAPK pathways, suppressing NLRP3 inflammasome activation, and promoting AMPK signaling, thereby reducing IL-1β release and tissue injury.